To inspire the next wave of research-driven innovation in healthcare, we’re partnering with research pioneers, like the Broad Institute of MIT and Harvard and Vanderbilt University to broaden access to large genomic data sets and state-of-the-art tools to analyze them. Together, Verily and the Broad Institute have created Terra: a scalable and secure platform that brings researchers to data sets through cloud-based technology, and fosters collaboration across the ecosystem. In addition to leveraging the open-source tools and workbench available via Terra, researchers can develop new libraries and tools for multi-modal data analysis.
Most recently, we partnered with the National Institutes of Health (NIH) to provide secure access to the diverse datasets through Terra to researchers across several of its flagship initiatives, including All of Us and the Accelerating Medicines Partnership for Parkinson’s Disease.
All of Us is a longitudinal research study aimed at engaging 1 million U.S. participants to improve the ability to prevent and treat disease. Verily, Vanderbilt and the Broad Institute built the data research and support center, using Terra as the underlying platform through which qualified All of Us researchers can explore and analyze participant data during the study, propose additional studies, and make discoveries or correlations in the comprehensive data set.
Terra aims to identify and validate biomarkers; improve clinical trial design, patient stratification, monitoring of disease progression; and ultimately contribute to the identification of new pathways for therapeutic development."
AMP PD is a partnership between the Foundation of the National Institutes of Health (FNIH), the U.S. Food and Drug Administration (FDA) and partners Celgene, GSK, Pfizer, Sanofi, Verily, and the Michael J. Fox Foundation. The broader AMP collaboration unites the research community around several disease areas, and in the case of Parkinson’s Disease, aims to identify and validate biomarkers; improve clinical trial design, patient stratification, monitoring of disease progression; and ultimately contribute to the identification of new pathways for therapeutic development. Terra is the foundation for the AMP PD Knowledge Portal, which provides qualified researchers with complex data sets and tools to perform genome-wide analysis at a scale that was previously impossible. Through a single data use agreement, researchers can today apply for access to the knowledge portal and interact with the entire data set.
By uniting the research community through interoperable, secure technology, we move closer towards shared goals of discovery and evidence generation. Terra is currently used by thousands of researchers every month, and we plan for additional data sets, tools and controls to be available in the future.